HUP0000108A2 - Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására - Google Patents

Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására

Info

Publication number
HUP0000108A2
HUP0000108A2 HU0000108A HUP0000108A HUP0000108A2 HU P0000108 A2 HUP0000108 A2 HU P0000108A2 HU 0000108 A HU0000108 A HU 0000108A HU P0000108 A HUP0000108 A HU P0000108A HU P0000108 A2 HUP0000108 A2 HU P0000108A2
Authority
HU
Hungary
Prior art keywords
angiotensin
heart failure
antagonists
manufacture
symptomatic heart
Prior art date
Application number
HU0000108A
Other languages
English (en)
Inventor
Polly A. Beere
Paul I. Chang
Bertram Pitt
Ewa J. Rucinska
Robert Segal
Divakar Sharma
Duane B. Snavely
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704197.4A external-priority patent/GB9704197D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0000108A2 publication Critical patent/HUP0000108A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány angiotenzin II (AT1)-receptor-antagonista gyógyászatikészítmény előállítására való alkalmazására vonatkozik, amelykészítmény szimptómás szívelégtelenségtől szenvedő betegeknek (i) ahirtelen szívhalál csökkentése, (ii) a mortalitás és a hirtelenszívhalál csökkentése, (iii) a hirtelen szívhalál megelőzése vagy (iv)a kórházi ápolás csökkentése céljából történő kezelésére használhatóés az antagonista terápiásan hatásos mennyiségét tartalmazza. A fentigyógyászati készítmények előnyösen (I) általános képletűimidazolszármazékokat tartalmaznak hatóanyagként. Ó
HU0000108A 1997-01-10 1998-01-07 Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására HUP0000108A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3492797P 1997-01-10 1997-01-10
GBGB9704197.4A GB9704197D0 (en) 1997-02-28 1997-02-28 Method for reducing mortality with an angiotensin 11 antagonist
PCT/US1998/000534 WO1998030216A1 (en) 1997-01-10 1998-01-07 Use of angiotensin ii antagonists to treat symptomatic heart failure

Publications (1)

Publication Number Publication Date
HUP0000108A2 true HUP0000108A2 (hu) 2001-04-28

Family

ID=26311085

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000108A HUP0000108A2 (hu) 1997-01-10 1998-01-07 Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására

Country Status (18)

Country Link
EP (1) EP0966282B1 (hu)
JP (1) JP2000508347A (hu)
KR (1) KR20000070046A (hu)
CN (1) CN1249682A (hu)
AT (1) ATE243515T1 (hu)
AU (1) AU729881B2 (hu)
CA (1) CA2277018C (hu)
DE (1) DE69815822T2 (hu)
DK (1) DK0966282T3 (hu)
EA (1) EA199900635A1 (hu)
EE (1) EE9900278A (hu)
ES (1) ES2200310T3 (hu)
HU (1) HUP0000108A2 (hu)
IL (1) IL130599A0 (hu)
NO (1) NO993399L (hu)
PT (1) PT966282E (hu)
SK (1) SK92899A3 (hu)
WO (1) WO1998030216A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
AU2001234088B2 (en) * 2000-02-18 2005-12-01 Takeda Pharmaceutical Company Limited Tnf-alpha inhibitors
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
SI3626270T1 (sl) * 2013-08-26 2024-03-29 Novartis Ag Zdravljenje srčno-žilnih bolezni
CN109715615A (zh) 2016-06-29 2019-05-03 蒙特利尔大学 联芳甲基杂环

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507627A (ja) * 1995-06-07 1999-07-06 ジー．ディー．サール アンド カンパニー 充血性心不全症を処置するためのエポキシ−ステロイド系アルドステロン拮抗物質とアンギオテンシンｉｉ拮抗物質との組合せ治療

Also Published As

Publication number Publication date
ATE243515T1 (de) 2003-07-15
EA199900635A1 (ru) 2000-02-28
DE69815822D1 (de) 2003-07-31
KR20000070046A (ko) 2000-11-25
CN1249682A (zh) 2000-04-05
ES2200310T3 (es) 2004-03-01
EP0966282B1 (en) 2003-06-25
DK0966282T3 (da) 2003-09-29
WO1998030216A1 (en) 1998-07-16
PT966282E (pt) 2003-10-31
SK92899A3 (en) 2000-08-14
DE69815822T2 (de) 2004-05-06
NO993399L (no) 1999-09-09
EP0966282A1 (en) 1999-12-29
JP2000508347A (ja) 2000-07-04
AU6021898A (en) 1998-08-03
AU729881B2 (en) 2001-02-15
CA2277018C (en) 2006-10-03
EE9900278A (et) 2000-02-15
IL130599A0 (en) 2000-06-01
NO993399D0 (no) 1999-07-09
CA2277018A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
TR200003158T2 (tr) Jelleşebilen farmasötik bileşimler
SE9901573D0 (sv) New compounds
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
HK1035335A1 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents p romoting the healing of wounds, to the upper respiratory tract and/or the ear
HUP0400553A2 (hu) Gyógyászati készítmények
CN111050767A (zh) 预防或治疗睡眠障碍的组合物
ATE322878T1 (de) Biotin enthaltende galenische formulierung
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
HUP0000108A2 (hu) Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
SE0002476D0 (sv) New compounds
JP2001510826A5 (hu)
CA2348882A1 (en) Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
SE9901572D0 (sv) New compounds
FR2420344A1 (fr) Nouveaux oxime-ethers, leur preparation et leur application therapeutique.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
AR026631A1 (es) ''3-4-dihidroquinazolinas 5,6-disustituidas''
CA2493208A1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
SE8900751L (sv) Farmaceutisk komposition
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları